PT1135158E - Vacinas intensificadas a base de peptidos de imunoglobulina e quimerica - Google Patents
Vacinas intensificadas a base de peptidos de imunoglobulina e quimericaInfo
- Publication number
- PT1135158E PT1135158E PT99963705T PT99963705T PT1135158E PT 1135158 E PT1135158 E PT 1135158E PT 99963705 T PT99963705 T PT 99963705T PT 99963705 T PT99963705 T PT 99963705T PT 1135158 E PT1135158 E PT 1135158E
- Authority
- PT
- Portugal
- Prior art keywords
- immunogenic polypeptides
- methods
- mammal
- ige
- nucleic acid
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 108091006116 chimeric peptides Proteins 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 230000002163 immunogen Effects 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 241000124008 Mammalia Species 0.000 abstract 4
- 239000000463 material Substances 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10665298P | 1998-11-02 | 1998-11-02 | |
| US09/401,636 US6913749B2 (en) | 1998-11-02 | 1999-09-22 | Immunogenic polypeptides for inducing anti-self IgE responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1135158E true PT1135158E (pt) | 2006-05-31 |
Family
ID=26803871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT99963705T PT1135158E (pt) | 1998-11-02 | 1999-10-21 | Vacinas intensificadas a base de peptidos de imunoglobulina e quimerica |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US6913749B2 (enExample) |
| EP (1) | EP1135158B1 (enExample) |
| JP (2) | JP4205861B2 (enExample) |
| KR (1) | KR100559918B1 (enExample) |
| AT (1) | ATE314087T1 (enExample) |
| AU (1) | AU771889B2 (enExample) |
| CA (1) | CA2348756A1 (enExample) |
| DE (1) | DE69929240T2 (enExample) |
| DK (1) | DK1135158T3 (enExample) |
| ES (1) | ES2255325T3 (enExample) |
| HU (1) | HUP0105392A3 (enExample) |
| IL (1) | IL142582A0 (enExample) |
| NO (1) | NO20012135L (enExample) |
| NZ (1) | NZ511079A (enExample) |
| PL (1) | PL348611A1 (enExample) |
| PT (1) | PT1135158E (enExample) |
| WO (1) | WO2000025722A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7658101A (en) * | 2000-07-28 | 2002-02-13 | Cytos Biotechnology Ag | Compositions for inducing self-specific anti-ige antibodies and uses thereof |
| EP2361635A3 (en) * | 2000-08-30 | 2011-09-14 | Pfizer Products Inc. | Anti IgE vaccines |
| JP2004508028A (ja) * | 2000-09-06 | 2004-03-18 | ファーメクサ エイ／エス | ＩｇＥをダウン−レギュレートさせる方法 |
| CA2698079C (en) | 2001-02-20 | 2015-01-13 | Ortho-Mcneil Pharmaceutical, Inc. | A cell therapy method for the treatment of tumors |
| US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
| ES2329453T3 (es) * | 2001-05-15 | 2009-11-26 | Ortho Mcneil Janssen Pharm | Cebado ex-vivo para generar linfocitos t citotoxicos especificos del ligando cd40 para tratar enfermedades autoinmunitarias y alergicas. |
| JP2003047482A (ja) * | 2001-05-22 | 2003-02-18 | Pfizer Prod Inc | 非アナフィラキシー誘発性ＩｇＥワクチン |
| CA2486464A1 (en) * | 2002-05-21 | 2003-11-27 | Resistentia Pharmaceuticals Ab | Chimeric ige polypeptides and host cells |
| CA2497660A1 (en) * | 2002-09-05 | 2004-03-18 | Resistentia Pharmaceuticals Ab | Allergy vaccines |
| US20080118524A1 (en) * | 2006-10-20 | 2008-05-22 | Stefan Persson | Anti-IgE Vaccines |
| US20100166804A1 (en) * | 2007-05-23 | 2010-07-01 | Dennis Penn | Methods |
| WO2009142772A2 (en) * | 2008-05-23 | 2009-11-26 | Mastcell Pharmaceuticals, Inc. | Methods and treatment for allergies and inflammation associated with gastrointestinal diseases |
| WO2010067286A2 (en) | 2008-12-09 | 2010-06-17 | Pfizer Vaccines Llc | IgE CH3 PEPTIDE VACCINE |
| EP2942061A3 (en) | 2010-06-07 | 2016-01-13 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
| US9187553B2 (en) * | 2012-01-25 | 2015-11-17 | Swey-Shen Chen | Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold |
| WO2013156054A1 (en) | 2012-04-16 | 2013-10-24 | Universität Stuttgart | The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity |
| EP2862873B1 (en) | 2012-06-18 | 2020-04-29 | Nippon Zenyaku Kogyo Co., Ltd. | IgE PEPTIDE VACCINE |
| SG11201806427WA (en) | 2016-02-16 | 2018-08-30 | Regeneron Pharma | Non-human animals having a mutant kynureninase gene |
| EP4582442A3 (en) | 2019-06-24 | 2025-10-29 | Universität Stuttgart | Tnfr2 agonists with improved stability |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4767842A (en) | 1973-05-07 | 1988-08-30 | The Ohio State University | Antigenic modification of polypeptides |
| US5698201A (en) | 1973-05-07 | 1997-12-16 | The Ohio State University | Method for treatment of antigenically modified polypeptides |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4483793A (en) | 1982-10-04 | 1984-11-20 | The Regents Of The University Of California | Dimeric oligopeptides as heptenic epitopic sites for hepatitis |
| US4782137A (en) | 1984-01-24 | 1988-11-01 | Immunex Corporation | Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same |
| US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5175385A (en) | 1987-09-03 | 1992-12-29 | Ohio University/Edison Animal Biotechnolgy Center | Virus-resistant transgenic mice |
| GB8727045D0 (en) | 1987-11-19 | 1987-12-23 | Research Corp Ltd | Immunoglobulin e competitor |
| US5254671A (en) * | 1990-04-27 | 1993-10-19 | Tanox Biosystems, Inc. | Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor |
| DE122006000007I2 (de) | 1987-12-31 | 2008-03-27 | Tanox Inc | -tragenden b-lymphocyten befinden. |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| GB8910263D0 (en) | 1989-05-04 | 1989-06-21 | Ciba Geigy Ag | Monoclonal antibodies specific for an immunoglobulin isotype |
| GB8913737D0 (en) | 1989-06-15 | 1989-08-02 | Univ Birmingham | A novel anti-allergy treatment |
| US5955076A (en) | 1989-06-15 | 1999-09-21 | Peptide Therapeutics Limited | Immunoactive peptides and antibodies and their use in anti-allergy treatment |
| AU651949B2 (en) | 1989-07-14 | 1994-08-11 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
| US5733553A (en) | 1989-09-29 | 1998-03-31 | Talwar; Gursaran Prasad | Recombinant birth control vaccine |
| AU645783B2 (en) | 1990-01-23 | 1994-01-27 | Tanox Biosystems, Inc. | Extracellular segments of human epsilon immunoglobulin anchoring peptides and antibodies specific therefor |
| EP0605410B1 (en) | 1990-05-25 | 1995-08-16 | Peptide Therapeutics Limited | Immunodiagnostic assay for rheumatoid arthritis |
| US5196197A (en) | 1990-08-29 | 1993-03-23 | National Institute Of Immunology | Reversible fertility control for prevention of pregnancy in females |
| FI932477L (fi) * | 1990-12-13 | 1993-06-11 | Immunex Corp | Receptorer foer leukemi-inhiberande faktor |
| SE9102808L (sv) | 1991-09-26 | 1993-03-27 | Lars T Hellman Inst F Immunolo | Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner |
| US5837686A (en) | 1991-11-25 | 1998-11-17 | Peptide Therapeutics Limited | Peptides and antibodies for treatment of rheumatoid arthritis |
| EP0662085A1 (en) | 1992-09-01 | 1995-07-12 | International Centre for Genetic Engineering and Biotechnology | Peptide showing cross-reactivity with the anti-hepatitis b surface antigen antiserum |
| WO1994008601A1 (en) | 1992-10-14 | 1994-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates |
| US5762931A (en) | 1992-12-31 | 1998-06-09 | National Institute Of Immunology | Anti-cancer utility of HCG vaccines |
| US5532142A (en) * | 1993-02-12 | 1996-07-02 | Board Of Regents, The University Of Texas System | Method of isolation and purification of fusion polypeptides |
| US5552537A (en) * | 1993-03-24 | 1996-09-03 | The Regents Of The University Of California | IgE isoforms and methods of use |
| US5501855A (en) | 1993-09-02 | 1996-03-26 | Talwar; Gursaran P. | Neem oil as a male contraceptive |
| DK96493D0 (da) * | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
| US5874085A (en) | 1993-11-10 | 1999-02-23 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Vaccine for enhanced production of IgA antibodies |
| FR2715304B1 (fr) | 1994-01-26 | 1996-04-26 | Merieux Serums Vaccins Pasteur | Vaccin anti-allergique. |
| CN1146772A (zh) | 1994-03-28 | 1997-04-02 | 美国联合生物医学公司 | 用于治疗过敏反应的合成肽免疫原 |
| US5651981A (en) * | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
| CA2203165A1 (en) | 1994-10-25 | 1996-05-02 | United Biomedical, Inc. | Synthetic ige membrane anchor peptide immunogens for the treatment of allergy |
| GB9422294D0 (en) | 1994-11-04 | 1994-12-21 | Peptide Therapeutics Ltd | Peptides for anti-allergy treatment |
| US6949244B1 (en) | 1995-12-20 | 2005-09-27 | The Board Of Trustees Of The University Of Kentucky | Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof |
| JPH08333390A (ja) | 1995-04-07 | 1996-12-17 | Hoechst Japan Ltd | ペプチド及びそれからなる自己免疫疾患治療剤 |
| AU716716B2 (en) | 1995-07-17 | 2000-03-02 | Medivir Uk Ltd | Cysteine protease inhibitors for use in treatment of IgE mediated allergic diseases |
| ZA966075B (en) | 1995-07-27 | 1998-01-19 | Genentech Inc | Protein formulation. |
| US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| AU719609B2 (en) | 1996-03-01 | 2000-05-11 | Novartis Ag | Peptide immunogens for vaccination against and treatment of allergy |
| CA2262001C (en) | 1996-08-05 | 2003-05-20 | President And Fellows Of Harvard College | Mhc binding peptide oligomers and methods of use |
| ZA983148B (en) | 1997-04-15 | 1999-10-15 | Ferring Farma Lab | Modified TNFÓ, DNA encoding such modified TNFÓ and vacines comprising said TNFÓ and DNA. |
| US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| US5891432A (en) * | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
| EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
| AU2674299A (en) | 1998-02-11 | 1999-08-30 | Maxygen, Inc. | Targeting of genetic vaccine vectors |
| US6299875B1 (en) | 1998-06-04 | 2001-10-09 | Panacea Pharmaceuticals, Llc | Methods to block IGE binding to cell surface receptors of mast cells |
| TWI227241B (en) | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
| DE69918146T2 (de) | 1998-10-05 | 2005-07-07 | Pharmexa A/S | Verfahren zur therapeutischen impfung |
| DE69939836D1 (de) | 1998-11-30 | 2008-12-11 | Cytos Biotechnology Ag | Molekulare anordnung von allergenen, verfahren zur deren herstellung und deren verwendung |
| GB9908533D0 (en) | 1999-04-14 | 1999-06-09 | Novartis Ag | Organic compounds |
| EA200101125A1 (ru) | 1999-04-23 | 2002-04-25 | Фармекса А/С | Способ понижающей регуляции активности il5 |
| AU7658101A (en) | 2000-07-28 | 2002-02-13 | Cytos Biotechnology Ag | Compositions for inducing self-specific anti-ige antibodies and uses thereof |
| JP2004508028A (ja) | 2000-09-06 | 2004-03-18 | ファーメクサ エイ／エス | ＩｇＥをダウン−レギュレートさせる方法 |
| US20040198961A1 (en) | 2001-06-15 | 2004-10-07 | Ling-Ling An | Fce fusion proteins for treatment of allergy and asthma |
-
1999
- 1999-09-22 US US09/401,636 patent/US6913749B2/en not_active Expired - Fee Related
- 1999-10-21 WO PCT/SE1999/001896 patent/WO2000025722A2/en not_active Ceased
- 1999-10-21 AU AU20081/00A patent/AU771889B2/en not_active Ceased
- 1999-10-21 DE DE69929240T patent/DE69929240T2/de not_active Expired - Lifetime
- 1999-10-21 PT PT99963705T patent/PT1135158E/pt unknown
- 1999-10-21 KR KR1020017005276A patent/KR100559918B1/ko not_active Expired - Fee Related
- 1999-10-21 AT AT99963705T patent/ATE314087T1/de not_active IP Right Cessation
- 1999-10-21 EP EP99963705A patent/EP1135158B1/en not_active Expired - Lifetime
- 1999-10-21 HU HU0105392A patent/HUP0105392A3/hu not_active Application Discontinuation
- 1999-10-21 ES ES99963705T patent/ES2255325T3/es not_active Expired - Lifetime
- 1999-10-21 DK DK99963705T patent/DK1135158T3/da active
- 1999-10-21 PL PL99348611A patent/PL348611A1/xx not_active Application Discontinuation
- 1999-10-21 IL IL14258299A patent/IL142582A0/xx not_active IP Right Cessation
- 1999-10-21 CA CA002348756A patent/CA2348756A1/en not_active Abandoned
- 1999-10-21 NZ NZ511079A patent/NZ511079A/en not_active IP Right Cessation
- 1999-10-21 JP JP2000579167A patent/JP4205861B2/ja not_active Expired - Fee Related
-
2001
- 2001-04-30 NO NO20012135A patent/NO20012135L/no unknown
-
2002
- 2002-06-19 US US10/176,664 patent/US7459158B2/en not_active Expired - Fee Related
-
2003
- 2003-09-29 US US10/673,594 patent/US20040076625A1/en not_active Abandoned
-
2005
- 2005-09-07 JP JP2005258648A patent/JP4188353B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002531064A (ja) | 2002-09-24 |
| JP4188353B2 (ja) | 2008-11-26 |
| ATE314087T1 (de) | 2006-01-15 |
| US7459158B2 (en) | 2008-12-02 |
| JP4205861B2 (ja) | 2009-01-07 |
| IL142582A0 (en) | 2002-03-10 |
| HUP0105392A2 (hu) | 2002-04-29 |
| DE69929240D1 (de) | 2006-02-02 |
| DE69929240T2 (de) | 2006-08-31 |
| KR100559918B1 (ko) | 2006-03-13 |
| HUP0105392A3 (en) | 2008-04-28 |
| PL348611A1 (en) | 2002-06-03 |
| AU2008100A (en) | 2000-05-22 |
| KR20010089364A (ko) | 2001-10-06 |
| NZ511079A (en) | 2003-08-29 |
| WO2000025722A2 (en) | 2000-05-11 |
| US20030031663A1 (en) | 2003-02-13 |
| EP1135158B1 (en) | 2005-12-28 |
| HK1042844A1 (en) | 2002-08-30 |
| ES2255325T3 (es) | 2006-06-16 |
| WO2000025722A3 (en) | 2000-10-12 |
| NO20012135D0 (no) | 2001-04-30 |
| US6913749B2 (en) | 2005-07-05 |
| CA2348756A1 (en) | 2000-05-11 |
| DK1135158T3 (da) | 2006-05-15 |
| EP1135158A2 (en) | 2001-09-26 |
| NO20012135L (no) | 2001-06-25 |
| US20010038843A1 (en) | 2001-11-08 |
| AU771889B2 (en) | 2004-04-08 |
| US20040076625A1 (en) | 2004-04-22 |
| JP2006068015A (ja) | 2006-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1135158E (pt) | Vacinas intensificadas a base de peptidos de imunoglobulina e quimerica | |
| NO346167B1 (no) | Humanisert, glykoomkonstruert Type II anti-CD20 antistoff og anvendelse derav, samt vertscelle og farmasøytisk sammensetning | |
| CY1121353T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις | |
| CY1122505T1 (el) | Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn | |
| DK1798288T3 (da) | Humane Toll-lignende receptorproteiner, relaterede reagenser og fremgangsmåder | |
| BR0113112A (pt) | Anticorpos, de integrina antidual, composições, métodos e usos | |
| AR052285A1 (es) | Moleculas de union al antigeno que fijan egfr, vectores que las codifican y usos de las mismas | |
| DE602004031017D1 (de) | Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort | |
| DK1167389T3 (da) | Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf | |
| ATE148168T1 (de) | Monoklonale antikörper | |
| TR200102034T2 (tr) | Anti kanser aşılaması için antikorların kullanılması | |
| BR0009781A (pt) | Anticorpos antiidiotìpicos contra anticorpos que inibem a ligação de imunoglobulina e ao seu receptor de alta afinidade | |
| WO2001057219A3 (en) | Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods | |
| EP1621209A3 (en) | Vaccines based on domains of chimeric immunoglobulin E peptides | |
| WO2004050111A3 (en) | Methods and materials for treating inflammatory conditions using a polypeptide comprising a self-c5 amino acid segment and a non-self amino acid segment | |
| Skea et al. | Adhesion-mediated enhancement of the adjuvant activity of alum | |
| Lou et al. | Destruction of zona pellucida of ovulated oocytes by anti-ZP3 antibodies: a potential mechanism of ZP-based contraceptive vaccine | |
| Robert et al. | Congenital toxoplasmosis: value of prenatal diagnosis and post-natal follow-up of newborns | |
| Asamar et al. | PCR diagnosis of toxoplasmosis in dead poetuses | |
| EA200500943A1 (ru) | Направленное действие на еденичные эпитопы | |
| CR8389A (es) | Anticuerpos cd20 con funcion del efector y afinidad de enlace al receptor fc mejoradas |